Grifols Class A/€GRF

1D1W1MYTD1Y5YMAX

About Grifols Class A

Grifols SA, operating under the ticker GRF, is a biopharmaceutical company specialized in the production of plasma-derived medicines. Founded in 1940 and headquartered in Barcelona, Spain, Grifols is engaged in the diagnosis, prevention, and treatment of a variety of diseases, with a strong focus on immunology, hematology, and intensive care sectors. The company operates globally, leveraging advanced technologies and rigorous quality processes to provide essential medical products.
Ticker
€GRF
Sector
Health
Primary listing
BME
Employees
25,258
Headquarters
Barcelona, Spain
Website
www.grifols.com

Grifols Class A Metrics

BasicAdvanced
€5.6B
14.06
€0.66
1.19
€0.07
0.72%

What the Analysts think about Grifols Class A

Analyst ratings (Buy, Hold, Sell) for Grifols Class A stock.
Analyst projections of the future price of Grifols Class A stock.

Bulls say / Bears say

The core Biopharma franchise is showing solid momentum. First-half Biopharma revenue rose 5.4% at constant currency, immunoglobulins grew 12.8%, and group profit increased 28.7% to €227 million, while the adjusted EBITDA margin reached 23.9%. (Grifols)
The balance-sheet risk has eased, even though leverage remains high. Grifols generated positive first-half free cash flow before M&A, raised liquidity to €2.03 billion, refinanced its 2027 maturities and has no significant debt maturities until the fourth quarter of 2028. (Grifols, Fitch Ratings)
Regional plasma sourcing could improve both resilience and margins. Egypt is being developed into a major non-US supply hub, with collection capacity targeted at up to three million litres a year by 2029, while the new operating model should better match sourcing costs with regional pricing. (Grifols, Grifols)
Debt is still a material equity risk. Net leverage stood at about 4.2 times in the first half, so refinancing has mainly pushed out maturities rather than removed the need for sustained cash generation and deleveraging. (Grifols, Grifols)
Albumin remains a weak spot, particularly in China. Pricing concessions continued to weigh on first-half performance, leaving the company dependent on immunoglobulin growth to offset pressure elsewhere in the portfolio. (Grifols, TIKR.com)
The turnaround still requires demanding execution in the second half. First-half free cash flow before M&A was €91 million against full-year guidance of €500–575 million, while the closure of 29 US donation centres shows that the plasma network is still being reshaped and carries restructuring risk. (Grifols, MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.

Grifols Class A Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Grifols Class A Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Grifols Class A

AllEURGBPUSD
Funds
Fund name
Fund size
€GRF weighting
Xtrackers Spain€XESD
€269M0.32%
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.18%
Xtrackers MSCI Europe Small Cap£XXSC
£2.8B0.18%
iShares STOXX Europe 600 Health Care€EXV4
€687M0.17%
iShares Dow Jones Eurozone Sustainability Screened€EXXV
€217M0.11%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.